Allergan welcomes findings of UK cosmetic surgery review

Allergan has reacted positively to the recent publication of the UK's review of the regulation of cosmetic interventions, chaired by Professor Sir Bruce Keogh.

The company has endorsed the report's recommendation for new regulatory changes to classify all cosmetic implants – including dermal fillers – as medical devices, while supporting calls to strengthen the existing European Medical Device Directive.

It also backed plans to set up accredited training standards for healthcare professionals administering cosmetic implants and efforts to improve consultation and record keeping of patient treatments.

Allergan was keen to indicate that its dermal filler products Juvederm and Surgiderm already adhere to European regulations and are supported by conclusive amounts of medical evidence and clinical experience.

Anthony Sauerman, general legal counsel for Allergan in Europe, said: "Many of the proposed changes are in line with our philosophy and should be adopted by all manufacturers entering the aesthetic market segment."

The review was launched last year in response to safety concerns highlighted by the recent PiP breast implant safety scandal.